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Abstract
Background: Adiposity greatly increases the risk of atherothrombotic events, a pathological condition where a
chronic state of oxidative stress is reported to play a major role. This study aimed to investigate the involvement of
(NO)-soluble guanylyl cyclase (sGC) signaling pathway in the platelet dysfunction from high fat-fed (HFF) rats.
Methods: Male Wistar rats were fed for 10 weeks with standard chow (SCD) or high-fat diet (HFD). ADP (10 μM)-
and thrombin (100 mU/ml)-induced washed platelet aggregation were evaluated. Measurement of intracellular
levels of ROS levels was carried out using flow cytometry. Cyclic GMP levels were evaluated using ELISA kits.
Results: High-fat fed rats exhibited significant increases in body weight, epididymal fat, fasting glucose levels and
glucose intolerance compared with SCD group. Platelet aggregation induced by ADP (n = 8) and thrombin from
HFD rats (n = 8) were significantly greater (P < 0.05) compared with SCD group. Platelet activation with ADP
increased by 54% the intraplatelet ROS production in HFD group, as measured by flow cytometry (n = 6). N-
acetylcysteine (NAC; 1 mM) and PEG-catalase (1000 U/ml) fully prevented the increased ROS production and
platelet hyperaggregability in HFD group. The NO donors sodium nitroprusside (SNP; 10 μM) and SNAP (10 μM), as
well as the NO-independent soluble guanylyl cyclase stimulator BAY 41-2272 (10 μM) inhibited the platelet
aggregation in HFD group with lower efficacy (P < 0.05) compared with SCD group. The cGMP levels in response
to these agents were also markedly lower in HFD group (P < 0.05). The prostacyclin analogue iloprost (1 μM)
reduced platelet aggregation in HFD and SCD rats in a similar fashion (n = 4).
Conclusions: Metabolic abnormalities as consequence of HFD cause platelet hyperaggregability involving
enhanced intraplatelet ROS production and decreased NO bioavailability that appear to be accompanied by
potential defects in the prosthetic haem group of soluble guanylyl cyclase.
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Background
Platelets play an important physiological function in
haemostasis system in response to vascular injury by
preventing hemorrhage [1]. Effective platelet adhesion
and aggregation require the synergistic contribution of
multiple receptor-ligand interactions that transmit acti-
vating signals initiating a range of platelet biochemical
and morphological responses, linked to cytoskeleton
remodeling, granule secretion and the generation and
release of endogenous soluble agonists, such as ADP
and thromboxane A2 (TXA2) [2-5].
Endothelial cell-derived nitric oxide (NO) exerts an
inhibitory effect in the platelet function by activation of
cGMP/PKG pathway, which in turn leads to reduction
in concentration of Ca2+, thus preventing adhesion and
aggregation of platelets to the vascular wall [6]. None-
theless, endothelium dysfunction, present in certain
pathological conditions, is characterized by a decreased
NO bioavailability which incites abnormal platelet acti-
vation leading to vascular thrombosis [7,8]. Platelet
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dysfunction is considered an end stage of cardiovascular
complications in type II diabetes mellitus, obesity and
atherosclerosis that results in clinical outcomes such as
myocardial infarction, stroke and peripheral artery dis-
ease [9].
Obesity is an important public health problem affecting
all ages and socioeconomic groups greatly elevating the
incidence of cardiovascular and endocrine-metabolic dis-
orders. A chronic state of oxidative stress and inflamma-
tion are the hallmark of adiposity that play a pivotal role
in the physiopathological events in this disorder [10,11].
These pro-inflammatory and pro-oxidant effects are asso-
ciated with increased reactive-oxygen species (ROS) pro-
duction and decreased NO bioavailability, which increases
the risk of athero-thrombotic events [12]. Nonetheless, the
exact mechanisms by which adiposity induces platelet dys-
function remain poorly investigated. In addition, most of
fatal cardiovascular events as consequence of thrombotic
complication are not associated with complete vascular
stenosis, but rather with alterations of pro-inflammatory
and pro-oxidant biomarkers, which can predict future car-
diovascular events. We hypothesized that intraplatelet
ROS production in adiposity contributes to thrombotic
events in endocrine-metabolic disorders. Therefore, we
have investigated the ex-vivo platelet reactivity in response
to ADP and thrombin in high fat-fed rats, and the involve-
ment of platelet-derived ROS and NO-cGMP pathway in
modulating the platelet reactivity.
Methods
Animals and high-fat diet
The experimental protocols were approved by the Ethi-
cal Principles in Animal Research adopted by the Brazi-
lian College for Animal Experimentation (COBEA) and
performed in compliance with the ARRIVE guidelines
on animal research [13]. Male Wistar rats were housed
in temperature-controlled rooms on a 12 h light-dark
cycle. The animals were housed two per cage and fed
for 10 weeks with either a standard chow diet (carbohy-
drate: 70%; protein: 20%; fat: 10%) or a high-fat diet that
induces obesity (carbohydrate: 29%; protein: 16%; fat:
55%), according to our previous work [14].
Body Weight, epididymal fat mass and glycemia
The body weight and epididymal fat mass were evalu-
ated in the beginning and at final time of the study. The
glucose concentration was measured in blood from the
tail vein (Accu-Check Performa, Roche Diagnostics,
Indianapolis, IN, USA).
Oral glucose tolerance test (OGTT) and insulin tolerance
test (ITT)
Oral glucose tolerance test was performed after 12 h of
fasting. Control and high-fat fed (HFF) obese rats
received a 20% glucose solution (2 g/kg) by gavage. Blood
samples were collected from tail vein at basal condition
and after 30, 60 and 120 min of glucose loading. Whole-
body insulin sensitivity was analyzed by the Insulin Tol-
erance Test (ITT). Venous blood samples were collected
before (0 min) and 15, 30 and 60 min after an intraperi-
toneal injection of regular insulin (0.75 U/kg).
Isolation of blood platelets and aggregation assays
Rats were anaesthetized with isoflurane, and blood was
collected from abdominal aorta in 1:9 (v/v) of ACD-C
(12.4 mM sodium citrate, 13 mM citric acid, 11 mM
glucose). Platelet-rich plasma (PRP) was obtained by
centrifugation of whole blood at 200 g for 15 min at
room temperature. Five milliliters of PRP were added to
7 ml of washing buffer (140 mM NaCl, 0.5 mM KCl, 12
mM trisodium citrate, 10 mM glucose, 12.5 mM sac-
charose, pH6), and centrifuged (800 g, 13 min). The pel-
let was resuspended in washing buffer, and the
procedure was repeated once. The platelets were gently
suspended in Krebs solution (118 mM NaCl, 25 mM
NaHCO3, 1.2 mM KH2PO4, 1.7 mM MgSO4, 5.6 mM
glucose, pH 7.4). The platelet number was adjusted to
1.2 × 108 platelets/ml in the presence of 1 mM CaCl2.
Platelet aggregation was measured in a two channel
aggregometer (Chronolog Lumi-Aggregometer model
560-Ca, Havertown, PA, USA) at 37°C with stirring
(1000 rpm). Platelet aggregation assays were carried
using ADP (10 μM) or thrombin (100 mU/ml).
Measurement of reactive-oxygen species (ROS) by flow
cytometry
Measurement of intracellular levels of ROS was carried
out according to a previous study [15]. Briefly, washed
platelets (obtained as detailed above) were resuspended
in Krebs-Ringer solution at 1.2 × 108 platelet/mL in the
presence of 1 mM of calcium and 5 μM of 2’-7’-dichlor-
ofluorescin diacetate (DCFH-DA). Platelet suspension
(500 μL) were pre-incubated with N-acetylcysteine
(NAC, 1 mM) or PEG-catalase (1000 U/ml) for 15 min
before addition of DCFH-DA. Platelet suspension was
then incubated or not with ADP (20 M) or H2O2 (8
mM; positive control) for 20 min. Platelet samples were
then centrifuged (800 g 10 min), and the pellet was
resuspended in Krebs solution (500 μL). Samples were
analyzed using a Becton Dickinson flow cytometer
(FACSCalibur, Becton Dickinson, San José, CA, USA)
equipped with a 488 nm wavelength argon laser, 510 ×
540 nm band pass filters. Platelets were identified by the
forward and side scatter signals. Ten thousand platelet
specific events were initially analyzed by the cytometer.
Non-activated and activated platelets were gated so as
not to analyze platelet aggregates and microparticles.
The gates were then analyzed for mean fluorescence.
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Extraction and measurement of cGMP
Washed platelets (1.2 × 108 platelets/mL) were incu-
bated with the phosphodiesterase inhibitor 3-isobutyl-l-
methyl-xanthine (IBMX; 2 mM) for 15 min. Next, plate-
lets were incubated with sodium nitroprusside (SNP, 10
μM), S-nitroso-N-acetylpenicillamine (SNAP, 10 μM) or
BAY 41-2272 (10 μM) for 3 min, after which the reac-
tion was interrupted by the addition of cold-acidified
absolute ethanol (67%, vol/vol), and samples were vigor-
ously agitated for 30 s. Cell samples were centrifuged
(4,000 g, 30 min at 4°C). Supernatants were dried at 55-
60°C under a stream of nitrogen. Cyclic GMP was mea-
sured by using a kit from Cayman Chemical (Ann
Arbor, MI). The assays were performed in duplicates.
The limit of cGMP detection is 1 pmol/mL.
Materials
Adenosine diphosphate (ADP), thrombin, PEG-catalase,
N-acetylcysteine (NAC), sodium nitroprusside, S-
nitroso-N-acetylpenicillamine (SNAP) were purchased
from Sigma Chem. Co. (St. Louis, MO, USA). 5-cyclo-
propyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-
3-yl]-pyrimidin-4-ylamine (BAY 41-2272) was provided
by Pharma Research Center, Bayer (Wuppertal, Ger-
many). Iloprost was supplied by Schering (Germany).
Statistical analysis
Data are expressed as means ± SEM of n rats. The sta-
tistical significance between groups was determined by
using one-way ANOVA followed by the Bonferroni test.
Where appropriate, unpaired Student’s t test was used
to compare specific groups. Significance was established
at P < 0.05.
Results
Body weight, oral glucose tolerance test (OGTT) and
insulin tolerant test (ITT)
Rats treated with high-fat diet (HFD) exhibited a signifi-
cant increase in body weight and epididymal fat com-
pared with animals receiving standard-chow diet (SCD),
approximately 20% and 135% (P < 0.05), respectively
(Table 1). Fasting glucose levels were significantly higher
in HFD compared with SCD group, about of 40% (P <
0.05). The OGTT showed that glucose levels remained
increased after glucose consumption in HFD in all eval-
uated time-points in comparison with SCD group (Fig-
ure 1A; n = 4-6). Insulin sensitivity was markedly
reduced in HFD compared with SCD rats (P < 0.05), as
assessed by the ITT (Figure 1B).
ADP- and thrombin-induced washed platelet aggregation
Platelet aggregation induced by ADP (10 μM) was sig-
nificantly greater (P < 0.05) in washed platelets obtained
from HFD compared with SCD group (80.0 ± 1.1% and
59.2 ± 1.5%, respectively; n = 8). Similarly, platelet
aggregation induced by thrombin (100 mU/ml) was
Table 1 Effect of high-fat diet on body weight,
epididymal fat weight and glucose levels
SCD HFD
Body weight (g) 457 ± 8.1 551 ± 17*
Epididymal fat (g) 7.6 ± 0.6 17.9 ± 1.5*
Glucose (mg/dl) 89 ± 3.8 127 ± 3.2*
Male Wistar rats were fed with either a standard chow diet (SCD) or high-fat
diet (HFD) during 10 weeks.










































Figure 1 Effect of 10-week high-fat diet (HFD) or standard chow diet (SCD) on oral glucose tolerance test (OGTT; panel A) and insulin
tolerant test (ITT; panel B). The values represent means ± SEM for n = 4-6 rats each group. * p <0.05 compared with control group.
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significantly greater (P < 0.05) in washed platelets
obtained from HFD compared with SCD group (81.2 ±
3.4% and 60.2 ± 3.1%, respectively; n = 8).
Generation of ROS in washed platelets
The basal production of intraplatelet ROS did not signif-
icantly change between HFD and SCD groups (Figure
2). In SCD group, activation of platelets with ADP (10
μM) did not significantly change the ROS production
compared with its respective basal ROS production.
However, in HFD group a marked increase in the intra-
platelet ROS production was found after activation by
ADP, by about of 54% (P < 0.001; Figure 2). Pretreat-
ment of platelets with NAC (1 mM) or PEG-catalase
(1000 U/ml) did not significantly affect the ROS produc-
tion in SCD, but prevented the increased ROS produc-
tion in platelets from HFD rats (n = 6 each group;
Figure 2).
Effect of NAC and PEG-catalase on platelet
hyperaggregability of HFF Rats
Pretreatment of platelets with NAC (1 mM, 3 min) or
PEG-catalase (1000 U/ml, 3 min) did not significantly
affect thrombin- or ADP-induced platelet aggregation in
SCD rats (n = 4-7; Figure 3). However, NAC and PEG-
catalase fully prevented the platelet hyperaggregability
induced by thrombin or ADP in HFD group (Figure 3).
Effect of sodium nitroprusside (SNP), S-nitroso-N-
acetylpenicillamine (SNAP) and BAY 41-2271 on platelet
aggregation and cGMP intracellular levels
In SCD rats, ADP-induced platelet aggregation was lar-
gely reduced by prior incubation with the NO donors
SNP (10 μM; n = 4) and SNAP (10 μM; n = 5), as well
as by the NO-independent soluble guanylyl cyclase sti-
mulator BAY 41-2272 (10 μM; n = 7), as shown in Fig-
ure 4A. The reduction of platelet aggregation by SNP,
SNAP and BAY 41-2272 were accompanied by 7.0-, 7.6-
and 12.3-fold increase (P < 0.001) in the amounts of
intracellular cGMP levels, respectively (Figure 4B). In
HFD rats, inhibition of ADP-induced platelet aggrega-
tion by SNP, SNAP and BAY-412272 was markedly
lower compared with SCD group (n = 4 each group;
Figure 4A). In addition, in HFD rats, SNP and SNAP
did not significantly increase the amounts of cGMP
above baseline (Figure 4B). The increases in cGMP by
BAY-412272 were also significantly lower in HFD com-
pared with SCD rats (Figure 4B). Incubation of platelets
with the soluble guanylyl cyclase inhibitor ODQ (10
μM, 10 min) before addition of SNP, SNAP and BAY
41-2272 (10 μM each) abolished the increase in the
cGMP levels (n = 3; not shown).
Effect of iloprost on platelet aggregation
Pretreatment of platelets with iloprost (1 μM, 3 min), a
prostacyclin analogue that acts directly in cAMP/PKA
signaling pathway, nearly abolished the ADP-induced
platelet aggregation, as observed in both SCD and HFD
rats (n = 4; Table 2). No statistical differences were
found between control and HFF rats.
Discussion
The present study shows that rats fed with high-fat diet
(HFD) exhibit ex-vivo platelet hyperaggregability to ADP
and thrombin, which is accompanied by higher intrapla-














Figure 2 Effect of high-fat diet in the generation of intraplatelet reactive-oxygen species (ROS). Male Wistar rats were fed with either a
standard chow diet (SCD) or high-fat diet (HFD) during 10 weeks. Washed platelets (1.2 × 108 platelets/ml) from SCD or HFF rats were pre-
incubated with N-acetylcysteine (NAC, 1 mM for 15 min) or PEG-catalase (1000 mU/ml, 15 min) and then stimulated with ADP (10 μM).
Generation of ROS was quantified by flow cytometry using 2’-7’-dichloroflurescin diacetate (DCFH-DA). Results are shown as mean ± SEM values
for n = 6-7. *P < 0.05 compared with SCD group. #P < 0.05 compared with ADP in HFF group. MFI = mean fluorescence index.
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was prevented by the antioxidant compounds PEG-cata-
lase and NAC in HFD group indicating a critical role for
intracellular ROS in this phenomenon. Moreover, the
NO donors SNP and SNAP, as well as the soluble guany-
lyl cyclase stimulator BAY 41-2272 showed a lower effi-
cacy in inhibiting the platelet aggregation in HFD rats,
possibly as a consequence of lower platelet cGMP pro-
ductions in this diet-induced obesity model.
Platelets, Hyperglycemia and Oxidative Stress
Evidences have shown that persistent hyperglycemia can
activate alternative glucose metabolism pathways, which
in turn result in the formation of deleterious products
derived from protein or lipid structure alterations
named advanced glycation end products (AGEs), which
can deeply affect the function of the cardiovascular sys-
tem [16]. In vascular system, the interaction of AGES
with their receptors (RAGE) can activate complex sig-
naling pathways causing increased production of inflam-
matory mediators and massive ROS generation,
resulting in reduced NO bioavailability and endothelium
dysfunction [17], as well as alterations in coagulation
system [18]. In cardiac tissues, the hyperglycemia-
induced ROS activate the MEK/ERK pathway to
increase GATA-4 phosphorylation, which in turn gener-
ates cardiac hypertrophy [19]. Hyperglycemia is also
associated with dysregulation of sympathetic innervation
to the myocardial tissues [20]. Thus, the mechanistic
event by which diet-induced obesity causes platelet dys-
function may therefore be associated with hyperglyce-
mia, which is consistent with the abnormality of the
OGTT and ITT in HFD group. Previous studies show
that acute hyperglycaemia enhances collagen-induced
platelet aggregation via increased mitochondrial O2
- pro-
duction [21]. Acute hyperglycaemia following an oral
glucose tolerance test or a carbohydrate-rich meal also
promotes platelet activation in vivo [22,23].
Radicals derived from oxygen represent the most
important class of ROS generated in living systems.
Superoxide anion (O2
-) is considered the primary ROS,
and it can further interact with other molecules, either



















































Figure 3 Effect of N-Acetylcysteine (NAC) and PEG-catalase on washed platelet aggregation of rats fed with a standard chow diet
(SCD) or high-fat diet (HFD) during 10 weeks. Washed platelets (1.2 × 108 platelets/ml) from SCD or HFD rats were stimulated with thrombin
(100 mU/ml; panel A) or ADP (10 μM; panel B) in the absence or the presence of NAC (1 mM) or PEG-catalase (1000 U/ml). Results are shown as
mean ± SEM values (n = 4-7). *P < 0.05 compared with untreated control group. #P < 0.05 compared with the respective untreated platelets.
Monteiro et al. Cardiovascular Diabetology 2012, 11:5
http://www.cardiab.com/content/11/1/5
Page 5 of 9
processes, to generate other physiological relevant ROS
such as hydrogen peroxyde (H2O2) and
-OH, as well as
peroxynitrite (ONOO-) [24]. Adiposity in humans is
reported to increase the risk of athero-thrombotic
events due partly to increased oxidative stress, as evalu-
ated by measurement of systemic biomarkers such as
serum levels of lipid peroxidation, TNF-a, free fatty
acids and oxidized LDL [12]. Different sources, includ-
ing platelets, may generate O2
- including the NADPH-
oxidase, xanthine oxidase and arachidonate-derived
prostaglandin-like metabolites [25-29]. However, the
contribution of intraplatelet ROS in modulating platelet
reactivity in conditions of adiposity has not been
explored. Therefore, this study was designed to explore
the ex-vivo washed platelet aggregation in HFD rats,
and the potential role of intraplatelet ROS production
and NO bioavailability in modulating platelet reactivity.
Our data showed that ADP- and thrombin-induced pla-
telet aggregation were significantly higher in HFD
group, which was accompanied by higher levels of ROS
production, as assessed by fluorescence assays using
DCFH [30]. Moreover, prior incubation of platelets with
the ROS scavengers PEG-catalase or NAC suppressed
both the increased ROS production and the hyperag-
gregability in HFD rats. Altogether, our data indicate



















































Figure 4 Effect of sodium nitroprusside (SNP), S-nitroso-N-acetylpenicillamine (SNAP) and BAY 41-2272 on washed platelet
aggregation (panel A) and cyclic GMP production (panel B) in rats fed with a standard chow diet (SCD) or high-fat diet (HFD) during
10 weeks. Washed platelets (1.2 × 108 platelets/ml) from SCD or HFD rats were stimulated with ADP (10 μM) in the absence or the presence of
SNP, SNAP or BAY 41-2272 (10 μM each). Results are shown as mean ± SEM values (n = 4-7). *P < 0.05 compared with untreated control group.
#P < 0.05 compared with the respective agent in control group.
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closely linked with enhanced intraplatelet ROS produc-
tion. A recent study showed that NAC, at concentra-
tions attainable with oral dosing [31], significantly
reduces ADP- and thrombin-induced platelet aggrega-
tion in whole blood of type 2 diabetic patients that is
associated with an enhancement of its antioxidant activ-
ity [32].
Increased oxidative stress may also influence platelet
function by decreasing NO bioavailability [12]. Nitric
oxide is a ROS involved in multiple biological functions
essential for the cardiovascular system and platelet func-
tion. Accordingly, in our study the ADP-induced platelet
aggregation was markedly reduced by the NO donors,
SNP and SNAP, in SCD rats, that was accompanied by
marked elevations in the cGMP levels, as expected.
Interestingly, in HFD rats, platelets were resistant to the
cGMP elevations in response to SNP and SNAP, as well
as to the inhibitory actions of these agents on platelet
aggregation. It is likely that excess of O2
- production in
platelets of HFD rats inactivates SNP- and SNAP-
derived NO. This is consistent with studies performed
in obese subjects and type 2 diabetic obese patients
where platelets are resistant to glyceryl nitrate and SNP
[33,34].
Platelet Hyperaggregability and Role of the Cyclic
Nucleotides
The soluble guanylyl cyclase (sGC) is a widely distribu-
ted signal transduction enzyme that, under activation by
NO, converts GTP into the second messenger cGMP
which in turn affects various downstream targets such
as protein kinases, cyclic nucleotide-gated channels or
phosphodiesterases [35]. One of the crucial pre-requi-
sites of the NO-mediated sGC activation is the presence
of the reduced haem moiety where its oxidation or loss
renders the enzyme insensitive to NO. Nitric oxide-
independent sGC activators have emerged as valuable
tools to elucidate the physiopathology of the NO-sGC-
cGMP signaling pathway [36]. The compound BAY 41-
2272 was reported as a haem-dependent and potent
NO-independent sGC stimulator [37]. BAY 41-2272
directly stimulates sGC and increases the sensitivity of
the enzyme to NO, generating significant amounts of
cGMP by stimulating the sGC mostly via NO-indepen-
dent mechanisms [38,39]. Through this mechanism,
BAY 41-2272 produces a variety of effects, including
anti-aggregatory effects. In our study, BAY 41-2272
greatly elevated the cGMP levels and nearly abolished
the platelet aggregation in SCD rats, as expected. How-
ever, the elevations of cGMP and inhibition of platelet
aggregation by BAY 41-2272 in HFD rats were signifi-
cantly lower compared with SCD group. This apparently
indicates that sGC of platelets from HFD rats display a
defect in producing appropriate amounts of intracellular
cGMP. In rat platelets, under physiological conditions,
inhibition of platelet aggregation by BAY 41-2272
requires the reduced form of sGC and the presence of
NO [40]. Furthermore, the free radical ONOO- is able
to oxidize the prosthetic haem group of sGC to its NO-
insensitive Fe3+ state [41-43]. If that takes place in plate-
lets from HFD rats, then BAY 41-2272 would be indeed
expected to be less effective in activating sGC. In this
aspect, it would be worth trying haem-independent sGC
activators such as HMR1766 and BAY 58-2667 because
they prevent sGC from oxidation-induced degradation,
as evidenced in chinese hamster ovary cell line and in
primary porcine endothelial cells [44]. Interestingly, the
direct sGC activator HMR1766 has been shown to
enhance the NO/cGMP-mediated signaling in platelets
from streptozotocin-induced diabetic rats, reducing pla-
telet-aggregates with other blood cells [45].
Besides the NO - cGMP - PDE5 pathway, the activa-
tion of platelets is inhibited by cAMP-elevating agents
[46]. Elevation of intracellular cAMP levels can be
achieved through the activation of adenylate cyclase
either directly or through appropriately coupled mem-
brane receptors, as well as by preventing the hydrolysis
of cAMP by the cyclic nucleotide phosphodiesterases. In
our study, the cAMP-elevating agent iloprost (stable
prostacyclin analogue) suppressed the ADP-induced pla-
telet aggregation in both SCD and HFD groups, exclud-
ing that hyperaggregability in HFD rats reflect changes
in the cAMP signaling pathway.
Conclusions
Our findings clearly show that metabolic abnormalities
as consequence of HFD in rats cause platelet hyperag-
gregability involving enhanced intraplatelet ROS produc-
tion and decreased NO bioavailability accompanied by
potential defects in the prosthetic haem group of sGC.
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Table 2 Effect of the prostacyclin analogue iloprost
(1 μM) in the ex vivo ADP-induced washed platelet
aggregation
SCD HFD
Control 54.2 ± 2.9% 70.7 ± 4.9%#
Iloprost 5.5 ± 1.5%* 5.7 ± 2.2%*
Male Wistar rats were fed with either a standard chow diet (SCD, n = 4) or
high-fat diet (HFD, n = 4) during 10 weeks.
*P < 0.05 compared with respective untreated platelets. #P < 0.05 compared
with untreated platelets in SCD group.
Monteiro et al. Cardiovascular Diabetology 2012, 11:5
http://www.cardiab.com/content/11/1/5
Page 7 of 9
Acknowledgements
Authors thank Fundação de Amparo à Pesquisa do Estado de São Paulo
(FAPESP) and Conselho Nacional de Desenvolvimento Científico e
Tecnológico (CNPq) for financial support.
Author details
1Department of Pharmacology, Faculty of Medical Sciences, University of
Campinas (UNICAMP), Campinas, Sao Paulo, Brazil. 2Department of Physical
Education, Institute of Bioscience, UNESP, Rio Claro, Sao Paulo, Brazil.
Authors’ contributions
AZ and EA carried out interpreting the data and writing the manuscript;
PFM, RPM, MAD, MEC, MELP and SM carried out data acquisition and
reviewing statistical analysis. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 2 December 2011 Accepted: 16 January 2012
Published: 16 January 2012
References
1. Andrews RK, Berndt MC: Platelet physiology and thrombosis. Thromb Res
2004, 114:447-53.
2. Denis CV, Wagner DD: Platelet adhesion receptors and their ligands in
mouse models of thrombosis. Arterioscler Thromb Vasc Biol 2007,
27:728-39.
3. Jackson SP: The growing complexity of platelet aggregation. Blood 2007,
109:5087-95.
4. Varga-Szabo D, Pleines I, Nieswandt B: Cell adhesion mechanisms in
platelets. Arterioscler Thromb Vasc Biol 2008, 28:403-12.
5. Wei AH, Schoenwaelder SM, Andrews RK, Jackson SP: New insights into
the haemostatic function of platelets. Br J Haematol 2009, 147:415-30.
6. Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL: Platelets and shear
stress. Blood 1996, 88:1525-41.
7. Schäfer A, Bauersachs J: Endothelial dysfunction, impaired endogenous
platelet inhibition and platelet activation in diabetes and
atherosclerosis. Curr Vasc Pharmacol 2008, 6:52-60.
8. Rivera J, Lozano ML, Navarro-Núñez L, Vicente V: Platelet receptors and
signaling in the dynamics of thrombus formation. Haematologica 2009,
94:700-711.
9. Libby P, Simon DI: Inflammation and thrombosis: the clot thickens.
Circulation 2001, 103:1718-1720.
10. Packard RR, Libby P: Inflammation in atherosclerosis: from vascular
biology to biomarker discovery and risk prediction. Clin Chem 2008,
54:24-38.
11. De Caterina R, Massaro M, Scoditti E, Annunziata Carluccio M:
Pharmacological modulation of vascular inflammation in
atherothrombosis. Ann N Y Acad Sci 2010, 1207:23-31.
12. Anfossi G, Russo I, Trovati M: Platelet dysfunction in central obesity. Nutr
Metab Cardiovasc Dis 2009, 19:440-449.
13. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG: Improving
bioscience research reporting: the ARRIVE guidelines for reporting
animal research. PloS Biol 2010, 8:e1000412.
14. Calixto MC, Lintomen L, Schenka A, Saad MJ, Zanesco A, Antunes E:
Obesity enhances eosinophilic inflammation in a murine model of
allergic asthma. Br J Pharmacol 2010, 159:617-625.
15. Possel H, Noack H, Augustin W, Keilhoff G, Wolf G: 2,7-
Dihydrodichlorofluorescein diacetate as a fluorescent marker for
peroxynitrite formation. FEBS Lett 1997, 416:175-178.
16. Grillo MA, Colombatto S: Advanced glycation end-products (AGEs):
involvement in aging and in neurodegenerative diseases. Amino Acids
2008, 35:29-36.
17. Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced glycation end
products: sparking the development of diabetic vascular injury.
Circulation 2006, 114:597-605.
18. Won SJ, Tang XN, Suh SW, Yenari MA, Swanson RA: Hyperglycemia
promotes tissue plasminogen activator-induced hemorrhage by
Increasing superoxide production. Ann Neurol 2011, 70(4):583-590.
19. Ku PM, Chen LJ, Liang JR, Cheng KC, Li YX, Cheng JT: Molecular role of
GATA binding protein 4 (GATA-4) in hyperglycemia-induced reduction
of cardiac contractility. Cardiovasc Diabetol 2011, 10:57.
20. Thackeray JT, Radziuk J, Harper ME, Suuronen EJ, Ascah KJ, Beanlands RS,
Dasilva JN: Sympathetic nervous dysregulation in the absence of systolic
left ventricular dysfunction in a rat model of insulin resistance with
hyperglycemia. Cardiovasc Diabetol 2011, 10:75.
21. Yamagishi SI, Edelstein D, Du XL, Brownlee M: Hyperglycemia potentiates
collagen-induced platelet activation through mitochondrial superoxide
overproduction. Diabetes 2001, 50:1491-1494.
22. Yngen M, Ostenson CG, Li N, Hjemdahl P, Wallén NH: Acute hyperglycemia
increases soluble P-selectin in male patients with mild diabetes mellitus.
Blood Coagul Fibrinolysis 2001, 12:109-116.
23. Yngen M, Ostenson CG, Hjemdahl P, Wallén NH: Meal-induced platelet
activation in Type 2 diabetes mellitus: effects of treatment with
repaglinide and glibenclamide. Diabet Med 2006, 23:134-140.
24. Gresele P, Cerletti C, Guglielmini G, Pignatelli P, de Gaetano G, Violi F:
Effects of resveratrol and other wine polyphenols on vascular function:
an update. J Nutr Biochem 2011, 22:201-211.
25. Seno T, Inoue N, Gao D, Okuda M, Sumi Y, Matsui K, Yamada S, Hirata KI,
Kawashima S, Tawa R, Imajoh-Ohmi S, Sakurai H, Yokoyama M: Involvement
of NADH/NADPH oxidase in human platelet ROS production. Thromb Res
2001, 103:399-409.
26. Wachowicz B, Olas B, Zbikowska HM, Buczyński A: Generation of reactive
oxygen species in blood platelets. Platelets 2002, 13:175-182.
27. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F:
gp91phox-dependent expression of platelet CD40 ligand. Circulation
2004, 110:1326-1329.
28. Begonja AJ, Gambaryan S, Geiger J, Aktas B, Pozgajova M, Nieswandt B,
Walter U: Platelet NAD(P)H-oxidase-generated ROS production regulates
alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway.
Blood 2005, 106:2757-2560.
29. Arthur JF, Gardiner EE, Kenny D, Andrews RK, Berndt MC: Platelet receptor
redox regulation. Platelets 2008, 19:1-8.
30. Myhre O, Andersen JM, Aarnes H, Fonnum F: Evaluation of the probes
2’,7’-dichlorofluorescin diacetate, luminol, and lucigenin as indicators of
reactive species formation. Biochem Pharmacol 2003, 65:1575-1582.
31. Gibson KR, Neilson IL, Barrett F, Winterburn TJ, Sharma S, MacRury SM,
Megson IL: Evaluation of the antioxidant properties of N-acetylcysteine
in human platelets: prerequisite for bioconversion to glutathione for
antioxidant and antiplatelet activity. J Cardiovasc Pharmacol 2009,
54:319-326.
32. Gibson KR, Winterburn TJ, Barrett F, Sharma S, MacRury SM, Megson IL:
Therapeutic potential of N-acetylcysteine as an antiplatelet agent in
patientswith type-2 diabetes. Cardiovasc Diabetol 2011, 10:43-51.
33. Anfossi G, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L,
Cavalot F, Trovati M: Platelet resistance to nitrates in obesity and obese
NIDDM, and normal platelet sensitivity to both insulin and nitrates in
lean NIDDM. Diabetes Care 1998, 21:121-126.
34. Anfossi G, Russo I, Massucco P, Mattiello L, Doronzo G, De Salve A,
Trovati M: Impaired synthesis and action of antiaggregating cyclic
nucleotides in platelets from obese subjects: possible role in platelet
hyperactivation in obesity. Eur J Clin Invest 2004, 34:482-489.
35. Francis SH, Busch JL, Corbin JD, Sibley D: cGMP-dependent protein
kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.
Pharmacol Rev 2010, 62:525-63.
36. Stasch JP, Hobbs AJN: NO-independent, haem-dependent soluble
guanylate cyclase stimulators. Handb Exp Pharmacol 2009, 191:277-308.
37. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A,
Gerzer R, Minuth T, Perzborn E, Pleiss U, Schröder H, Schroeder W, Stahl E,
Steinke W, Straub A, Schramm M: NO-independent regulatory site on
soluble guanylate cyclase. Nature 2001, 410:212-215.
38. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T,
Perzborn E, Schramm M, Straub A: Pharmacological actions of a novel
NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro
studies. Br J Pharmacol 2002, 135:333-343.
39. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HH, Stasch JPN: NO-
independent stimulators and activators of soluble guanylate cyclase:
discovery and therapeutic potential. Nat Rev Drug Discov 2006, 5:755-678.
40. Roger S, Badier-Commander C, Paysant J, Cordi A, Verbeuren TJ, Félétou M:
The anti-aggregating effect of BAY 41-2272, a stimulator of soluble
Monteiro et al. Cardiovascular Diabetology 2012, 11:5
http://www.cardiab.com/content/11/1/5
Page 8 of 9
guanylyl cyclase, requires the presence of nitric oxide. Br J Pharmacol
2010, 161:1044-1058.
41. Gladwin MT: Deconstructing endothelial dysfunction: soluble guanylyl
cyclase oxidation and the NO resistance syndrome. J Clin Invest 2006,
116:2330-2332.
42. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Arum Kumar HS,
Meurer S, Taye A, Knorr A, Lapp H, Müller H, Turgay Y, Rothkegel C,
Tersteegen A, Kemp-Harper B, Müller-Esterl W, Schmidt HH: Targeting the
heme-oxidized nitric oxide receptor for selective vasodilatation of
diseased blood vessels. J Clin Invest 2006, 116:2552-2561.
43. Chirkov YY, Horowitz JD: Impaired tissue responsiveness to organic
nitrates and nitric oxide: a new therapeutic frontier? Pharmacol Ther
2007, 116:287-305.
44. Hoffmann LS, Schmidt PM, Keim Y, Schaefer S, Schmidt HH, Stasch JP:
Distinct molecular requirements for activation or stabilization of soluble
guanylyl cyclase upon haem oxidation-induced degradation. Br J
Pharmacol 2009, 157:781-795.
45. Schäfer A, Flierl U, Kobsar A, Eigenthaler M, Ertl G, Bauersachs J: Soluble
guanylyl cyclase activation with HMR1766 attenuates platelet activation
in diabetic rats. Arterioscler Thromb Vasc Biol 2006, 26:2813-2818.
46. Noé L, Peeters K, Izzi B, Van Geet C, Freson K: Regulators of platelet cAMP
levels: clinical and therapeutic implications. Curr Med Chem 2010,
17:2897-2905.
doi:10.1186/1475-2840-11-5
Cite this article as: Monteiro et al.: Platelet hyperaggregability in high-
fat fed rats: A role for intraplatelet reactive-oxygen species production.
Cardiovascular Diabetology 2012 11:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Monteiro et al. Cardiovascular Diabetology 2012, 11:5
http://www.cardiab.com/content/11/1/5
Page 9 of 9
